Dvorkin Julia, De Luca Julián, Alvarez-Paggi Damian, Caballero Mauricio T
Fundación INFANT, Buenos Aires, Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Infect Drug Resist. 2023 Jan 27;16:595-605. doi: 10.2147/IDR.S373584. eCollection 2023.
Respiratory syncytial virus (RSV) has a major role in respiratory infections in young infants around the world. However, substantial progress has been made in recent years in the field of RSV. A wide variety of observational studies and clinical trials published in the past decade provide a thorough idea of the health and economic burden of RSV disease in the developing world. In this review, we discuss the impact of RSV burden of disease, major gaps in disease estimations, and challenges in generating new therapeutic options and an immune response against the virus, and briefly describe next generation technologies that are being evaluated.
呼吸道合胞病毒（RSV）在全球婴幼儿呼吸道感染中起主要作用。然而，近年来RSV领域已取得了重大进展。过去十年发表的大量观察性研究和临床试验，让人全面了解了RSV疾病在发展中国家造成的健康和经济负担。在本综述中，我们讨论了RSV疾病负担的影响、疾病估计中的主要差距、开发新治疗方案和针对该病毒的免疫反应所面临的挑战，并简要介绍了正在评估的下一代技术。
